Sydney-based Viral Vector Manufacturing Facility and Melbourne-headquartered Mirugen have signed a non-exclusive Letter of Intent to evaluate and potentially develop the company's AAV-based gene therapy candidate targeting Retinitis Pigmentosa.

Algorae Pharmaceuticals has appointed Troy Valentine as a Non-Executive Director, a move the company says will materially deepen its board capability in capital markets, life sciences governance and international listed-company leadership. 

AusBiotech has announced a new partnership designed to provide its members with discounted access to Oktopi’s AI-informed platform and to expand the services available through the organisation's Business Solutions Program.

Patrys has struck a binding agreement with Yale that transfers ownership of the deoxymab intellectual property to the university while securing Patrys a 50 per cent share of any future commercialisation revenue directly attributable to the deoxymab portfolio.

CLINUVEL has announced that Health Canada has granted a Notice of Compliance allowing SCENESSE to be marketed in the country for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria, a rare metabolic disorder that causes debilitating phototoxic reactions and burns after brief exposure to visible light.

OncoSil Medical has completed three manufacturing validation cycles with partner Cyclotek, producing more than 50 validation doses of its OncoSil device and establishing a dedicated Australian manufacturing capability.

Immutep has reported mature overall survival data from the investigator‑initiated INSIGHT‑003 trial that it says offer a hopeful signal for eftilagimod alfa, known as efti, in first-line non‑squamous non‑small cell lung cancer.

Dimerix has announced that patients who complete the ACTION3 Phase 3 trial and its open-label extension may be allowed to continue receiving the investigational candidate DMX-200 through post‑trial access pathways in key territories.

Ceryvyn Therapeutics has officially replaced the name Opthea after shareholders approved the change at an extraordinary meeting on 3 July 2026, and the company updated its registration with ASIC.

Researchers at Monash University say they have found a gene in animal models that could help explain why some women experience early loss of fertility and premature menopause.

Proteomics International Laboratories has secured a United States patent for PromarkerEndo, its proprietary blood test for diagnosing endometriosis, a development the company describes as a major step toward global commercialisation.

Seventeen of Australia’s leading medical and science organisations have come together to warn the Albanese Government that proposed changes to the Research and Development Tax Incentive risk hollowing out the country’s life sciences and medical technology sectors.

Australia’s largest life sciences private equity company, Brandon Capital, has announced a landmark exit as Novartis moves to acquire its portfolio company Myricx Bio in a deal valued at up to US$1.5 billion, including an upfront cash payment of US$1.1 billion and further milestone payments. 

The company said the funds raised will go towards the development of its lead allogeneic CAR T therapy, azer-cel, into calendar year 2027, including clinical and regulatory activities, manufacturing scale-up and general working capital.

Australian company Syntara and Parkinson’s Research Ventures have reported early signs that a novel anti-inflammatory candidate may reduce brain inflammation in people at high risk of developing Parkinson’s disease.

CEO and Managing Director Dr David Foster said, "Securing all regulatory and ethics approvals to commence this effort represents a significant milestone for galidesivir and the culmination of more than a year of collaboration with our partners in Uganda and the ACCEPT Africa Consortium."

Cartherics has been recognised as the Emerging Leader in Allogeneic Cell Therapy at the Asia Pacific Cell and Gene Therapy Excellence Awards 2026, a milestone that highlights the company's rise in the off-the-shelf immune cell therapy field.